Metro (MRU) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
4 Mar, 2026Executive summary
Q1 sales grew 3.3% year-over-year to CAD 5.3 billion, with adjusted EBITDA up 4.7% and adjusted EPS up 5.5%.
Net earnings declined 12.8% to CAD 226.3 million, but adjusted net earnings rose 1.3% to CAD 248.7 million, reflecting normalization after one-time costs.
Fully diluted EPS fell 9.5% to CAD 1.05, while adjusted EPS grew 5.5% to CAD 1.16.
Operations at the Toronto frozen food distribution center have fully resumed after a costly temporary shutdown.
Dividend per share increased 10.1% to CAD 0.4075.
Financial highlights
Adjusted EBITDA reached CAD 504.2 million, up 4.7% year-over-year, representing 9.5% of sales.
Adjusted net earnings were CAD 248.7 million, up 1.3% year-over-year; adjusted EPS was CAD 1.16, up 5.5%.
Gross margin was CAD 1.04 billion or 19.7% of sales, flat year-over-year.
Operating expenses as a percentage of sales increased to 10.5%, impacted by CAD 20.8 million in direct costs from the Toronto freezer shutdown.
Capital expenditures totaled CAD 61.9 million, down from CAD 89.3 million last year.
Outlook and guidance
CapEx for fiscal 2026 expected to reach approximately CAD 550 million, focused on retail network investment.
Plans to open a dozen discount stores and several major renovations in 2026.
Continued emphasis on value for customers through merchandising, private labels, and loyalty programs amid a challenging economic environment.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, net earnings up 17.6%, supply chain investments ongoing.MRU
Q2 20254 Mar 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Sales up 3.5%, stable margins, but net earnings fell 14.6% amid automation costs.MRU
Q3 20244 Mar 2026 - Q4 saw higher margins, strong pharmacy and online sales growth, and a completed supply chain overhaul.MRU
Q4 20244 Mar 2026 - Q3 sales rose 3.3%, adjusted EPS up 12.6%, with strong pharmacy and discount banner growth.MRU
Q3 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Strong results, board re-elections, and strategic growth plans highlighted, with rising dividends.MRU
AGM 20259 Jan 2026